PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
PLACARD
1 other identifier
observational
3,000
1 country
27
Brief Summary
The association between Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) is well established. Traditional risk factors for CVD and CKD are similar, with type 2 diabetes mellitus (T2DM) being the most prevalent risk factor. However, CKD is underdiagnosed and undertreated in patients with CVD. Further understanding of the combination of CKD in CVD patients is important to formulate prevention and treatment strategies for CVD patients and high-risk groups, reduce adverse events in CVD patients, and prevent progression of CKD to End Stage Renal Disease (ESRD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2023
27 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 21, 2023
CompletedFirst Submitted
Initial submission to the registry
December 27, 2023
CompletedFirst Posted
Study publicly available on registry
March 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2024
CompletedSeptember 19, 2024
September 1, 2024
7 months
December 27, 2023
September 10, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The prevalence of albuminuria
To assess the prevalence of albuminuria in patients who are combined with type 2 diabetes mellitus and different cardiovascular diseases in inpatient and outpatient cardiology departments of secondary and tertiary hospitals in China.
On the day of patients enrollment.
Secondary Outcomes (4)
Lthe prevalence of microalbuminuria and macroalbuminuria evels of microalbuminuria and macroalbuminuria
On the day of patients enrollment.
The prevalence of microalbuminuria and macroalbuminuria
On the day of patients enrollment.
To evaluate the related influence factors of albuminuria and the treatment patterns of CKD patients and non-CKD patients in cardiology departments;
On the day of patients enrollment.
Evaluate the management of patients with type 2 diabetes mellitus and cardiovascular disease across different levels of cardiology departments in hospitals.
On the day of patients enrollment.
Other Outcomes (1)
Exploratory Objective
On the day of patients enrollment.
Eligibility Criteria
This study will adopt a stratified, multi-level, and multi-center strategy for continuous screening to enroll patients who meet all inclusion criteria and none of the exclusion criteria. During the enrollment period, the Clinical Coordinator will communicate with and invite all potential patients attending the selected inpatient wards or the designated outpatient physicians
You may qualify if:
- Age ≥18 years old;
- Diagnosed T2DM combined with ≥1 CVD (hypertension, coronary heart disease, atrial fibrillation, heart failure);
- During the data collection period, they went to the outpatient clinic of the cardiology department of the research center, or received treatment in the cardiology department;
- Ability to self-sign informed consent (electronic /paper).
You may not qualify if:
- Pregnant or lactating women;
- Dialysis patients;
- Other diseases that lead to elevated albuminuria, such as severe infection, confirmed primary glomerular disease, etc.;
- Malignant tumors being treated (surgery, chemotherapy, radiotherapy or targeted therapy);
- Cachexia (CSS score ≥ 5 points);
- Severe liver disease (Child- Pugh grade C) ;
- Participated in an interventional clinical trial in the past three months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (27)
Beijing Sixth Hospital
Beijing, Beijing Municipality, China
Fangshan District First Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Chinese PLA Army Characteristic Medical Center
Chongqing, Chongqing Municipality, China
Haidong City Second People's Hospital
Haidong, Gansu, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Ruyang County People's Hospita
Luoyang, Henan, 471201, China
Luoyang Sixth People's Hospita
Luoyang, Henan, China
Yongcheng People's Hospital
Yongcheng, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Zhangjiagang Sixth People's Hospital
Zhangjiagang, Jiangsu, China
Shenyang Ninth People's Hospital
Shenyang, Liaoning, China
Shenyang Tenth People's Hospital
Shenyang, Liaoning, China
Jining First People's Hospital
Jining, Shandong, China
Tai'an First People's Hospital
Tai’an, Shandong, China
Weihai Central Hospital
Weihai, Shandong, China
Jing'an District Central Hospital of Shanghai
Shanghai, Shanghai Municipality, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University Qingpu Branch
Shanghai, Shanghai Municipality, China
Qinyuan County People's Hospital
Changzhi, Shanxi, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
XI Ail, Shanxi, China
The Fifth People's Hospital of Sichuan Province
Chengdu, Sichuan, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Taizhou Central Hospital
Taizhou, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Changsheng Ma, Doctor
Beijing Anzhen Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of Cardiology
Study Record Dates
First Submitted
December 27, 2023
First Posted
March 28, 2024
Study Start
December 21, 2023
Primary Completion
July 9, 2024
Study Completion
December 30, 2024
Last Updated
September 19, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share